@AlexSherryMD profile picture
Alexander Sherry @AlexSherryMD

Radiation oncologist @MayoRadOnc @MayoClinic | views = my own

Joined March 2020
  • Tweets 151
  • Following 395
  • Followers 586
24 Photos and videos
Alexander Sherry retweeted
Chad Tang, MD@ChadTangMD
16h
Excited for the interest in our biomarker work from the urologic oncology community @VincentWenxinXu @PavlosMsaouel @AlexSherryMD @kieko_hara @d_shapiro1 @MDAndersonnews
European Urology
@EUplatinum
16h
🏆 Congratulations to @ChadTangMD et al. on receiving our April IMPACT Award! This month's winning paper stands out for its contribution to understanding how we can better predict outcomes for patients with Oligometastatic Clear-cell Renal Cell Carcinoma — an important step forward for personalised care. Well deserved. 👏 #IMPACTAward #EuropeanUrology #renalcellcarcinoma #Oncology #Urology
2
8
36
2,155
Alexander Sherry retweeted
Chad Tang, MD@ChadTangMD
May 18
Replying to @GiulioFrancoli1
@GiulioFrancoli1 at #estro2026 presents early results of the randomized PERSIAN trial. Results are early showing excellent PSA response in both arms (mdt slightly better) but definitely more to come.
1
12
33
1,327
1/ Tremendous thanks to the patients, coauthors and all who made the EXTEND trial possible. The primary aggregated analysis is now available online @JCO_ASCO with ctDNA correlatives presented synchronously at @ESTRO_RT #ESTRO26
1
31
74
8,140
more replies
6/ EXTEND supports MDT SOC as a strategy in oligometastasis and opens the door to multiple promising new directions to further improve outcomes with MDT in oligometastasis,. such as ctDNA guided care meriting future RCTs
1
4
384
7/ My personal gratitude to PI @ChadTangMD for years of mentorship and guidance on this study. Full paper available here: ascopubs.org/doi/pdf/10.1200…
1
6
549
Alexander Sherry retweeted
Chad Tang, MD@ChadTangMD
May 17
Replying to @piet_ost
@piet_ost excellent presentation on the DART trial randomizing mdt and mdt 6 mo darolutamide in oligomet prostate cancer with temporary delay of progression only while the hormone therapy was being administere. #estro26
8
26
966
Alexander Sherry retweeted
Shankar Siva
@_ShankarSiva
Apr 28
New @EurUrol! Pooled trials @PeterMacCC / @UTMDAnderson shows adding Pembrolizumab to MDT for oligometastatic #kidneycancer ⬆️ PFS (28 vs 17 mo; HR 0.57), esp. after prior therapy - shorturl.at/WWvBg - Correlative data confirm MDT ICI-evoked immune activation #Kcsm #RadOnc
3
36
91
8,031
Alexander Sherry retweeted
Chad Tang, MD@ChadTangMD
Mar 4
Excited to review our paper on KIM-1 and ctDNA in oligomet RCC and the K-COMPASS prognostic model published this wk in @EuropeanUrology. Great collaboration between @UTMDAnderson and @DanaFarber. Specifically @VincentWenxinXu and @DrChoueiri Full paper: authors.elsevier.com/a/1mhMr…
4
37
93
9,155
Alexander Sherry retweeted
Pavlos Msaouel@PavlosMsaouel
Mar 1
This is how we finally start harnessing the untapped for decades power of *prognostic* modeling (not “predictive”) for biomarker development. Onwards! 🔬@ChadTangMD @VincentWenxinXu @AlexSherryMD @OncHahn @AmandaNizamMD @KidneyCancer @ebludmir @PGrivasMDPhD
Andy Hahn@OncHahn
Feb 28
The K-COMPASS study by @ChadTangMD shows how ctDNA and KIM-1 are prognostic and can be used to estimate treatment-free survival in patients with oligometastatic RCC #ASCOGU26 @PavlosMsaouel
1
11
31
2,841
Alexander Sherry retweeted
Matt Campbell MD, MS
@DocMattCampbell
Feb 28
At #GU26 a tremendous overview of optimal trial design by @PavlosMsaouel. Pavlos has repeatedly shown that even in very rare cancers, optimally designed studies can rapidly led to practice changing findings. A visionary in our field.
2
19
53
8,576
Alexander Sherry retweeted
Chad Tang, MD@ChadTangMD
Feb 3
Extremely excited to share our latest article published @TheLancetOncol a few hours ago: authors.elsevier.com/a/1mYT6…. The WOLVERINE individual patient meta-analysis was an international collaboration and part of X-MET collaboration. Goal was to evaluate MDT in oligomet prostate ca.

11
52
140
14,169
Alexander Sherry retweeted
Chad Tang, MD@ChadTangMD
25 Oct 2025
Thanks for @Uromigos for letting me chat about radiation in oligometastatic RCC. @_ShankarSiva @piet_ost @ndesai2005 @KidneyCancer @AlexSherryMD @ebludmir @ASTRO_org @ACKoongMDPhD @MDAndersonNews @VedangMurthy @PavlosMsaouel @salvolarosa
Uromigos
@Uromigos
24 Oct 2025
The UromigosLive 2025 meeting presents #UromigosShorts videos on GU Oncology topics. The videos with the most views win a prize at #UromigosLive November 7-8th in Nashville, TN. Below, Dr. Chad Tang discusses: Metastasis-directed Therapy in RCC.
4:49
11
32
3,919
Alexander Sherry retweeted
Chad Tang, MD@ChadTangMD
4 Sep 2025
Excited to share our recent @LancetOncology publication on sequential SBRT for oligometastatic clear cell RCC. Our outcomes show excellent outcomes in 121 patients with 1-5 metastases. @MDAndersonNews @myriadgenetics authors.elsevier.com/a/1ljMf…
19
74
203
25,395
Does the addition of MDT to standard of care continuous ADT improve outcomes for oligomet prostate ca? Happy to share the results of EXTEND evaluating this question alongside PI @ChadTangMD & many others
8
80
184
23,598
more replies
10/ Nonetheless EXTEND is a critical step forward for improving outcomes in oligomet prostate ca and supports the role of MDT with multiple ADT strategies.
1
5
881
11/ Many thanks to the outstanding study team/coordinators, collaborators & the pts and families who participated in the trial. My special gratitude for the mentorship of @ChadTangMD in this study. Full text: authors.elsevier.com/c/1lX0v…

1
15
847
Load more